Crinetics Pharmaceuticals (CRNX) Net Margin (2017 - 2026)
Crinetics Pharmaceuticals (CRNX) recorded quarterly Net Margin of 1189.81% in Q1 2026, up 40.23% quarter-over-quarter from 1990.5% in Q4 2025, and up 2556116.0% on a YoY basis from N/an in Q1 2025.
Crinetics Pharmaceuticals (CRNX) Net Margin (2017 - 2026) Analysis & Trends
Crinetics Pharmaceuticals' Net Margin history runs 10 years deep, the most recent figure standing at 1189.81% for Q1 2026.
- In Q1 2026, Net Margin rose 2556116.0% year-over-year to 1189.81%; the TTM figure through Mar 2026 stood at 2745.57% (up 4041706.0% YoY), while the FY2025 annual figure was 6046.22%, up 2262924.0% from the prior year.
- Net Margin was 1189.81% for Q1 2026 at Crinetics Pharmaceuticals, up from 1990.5% in the prior quarter.
- In the past five years, Net Margin ranged from a high of 1074.23% in Q1 2022 to a low of 90972.73% in Q3 2025.
- Historically, Net Margin has averaged 15036.21% across 5 years, with a median of 9400.75% in 2022.
- The sharpest annual moves came in 2025 and 2026: Net Margin plunged 1640581 bps in 2025, then soared 2556116 bps in 2026.
- A 5-year view of Net Margin shows it stood at 6438.93% in 2022, then slumped by 153 bps to 16302.89% in 2023, then decreased by 14 bps to 18556.89% in 2024, then jumped by 89 bps to 1990.5% in 2025, then jumped by 40 bps to 1189.81% in 2026.
- The last three Net Margin figures came in at 1189.81% (Q1 2026), 1990.5% (Q4 2025), and 90972.73% (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 0.82% |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 34.53% |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | - |
| 10 | Crinetics Pharmaceuticals | 3.75 Bn | 3.75 Bn | 10.53 Mn | -1,189.81% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -1,189.81% |
| Dec 31, 2025 | -1,990.50% |
| Sep 30, 2025 | -90,972.73% |
| Jun 30, 2025 | -11,217.94% |
| Mar 31, 2025 | -26,750.97% |
| Jun 30, 2024 | -18,556.89% |
| Mar 31, 2024 | -10,345.16% |
| Sep 30, 2023 | -16,302.89% |
| Jun 30, 2023 | -5,150.61% |
| Mar 31, 2023 | -1,714.82% |
| Dec 31, 2022 | -6,438.93% |
| Sep 30, 2022 | -9,160.26% |
| Jun 30, 2022 | -9,641.23% |
| Mar 31, 2022 | -1,074.23% |
| Dec 31, 2021 | -2,857.88% |
| Dec 31, 2020 | 30,616.90% |
| Mar 31, 2020 | -24,261.97% |
| Dec 31, 2019 | -4,535.51% |
| Sep 30, 2019 | -2,850.30% |
| Mar 31, 2019 | -2,461.58% |